Ketorolac

Generic Name
Ketorolac
Brand Names
Acular, Acuvail, Omidria, Readysharp Anesthetics Plus Ketorolac, Sprix, Toradol, Toronova Suik
Drug Type
Small Molecule
Chemical Formula
C15H13NO3
CAS Number
74103-06-3
Unique Ingredient Identifier
YZI5105V0L
Background

Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.

It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.

Indication

Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties. It is indicated for short term management of acute pain that requires the calibre of pain management offered by opioids. Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders and headaches among other ailments. Regardless of the etiology of pain, patients should use the lowest possible dose, and avoid using ketorolac for an extended period of time (ideally ≤ 5 days). A benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac use.

Associated Conditions
Acute Migraine, Eye Pain, Inflammation, Macular Edema, Cystoid, Ocular Itching, Pericarditis Acute, Pseudophakic Cystoid Macular Oedema, Severe Acute Pain, Acute, moderate Pain, Chronic aphakic cystoid macular edema, Intraoperative miosis, Postoperative ocular pain
Associated Therapies
-

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

First Posted Date
2017-02-28
Last Posted Date
2019-01-10
Lead Sponsor
University of Wisconsin, Madison
Registration Number
NCT03066115
Locations
🇺🇸

University of Wisconsin, Madison, Madison, Wisconsin, United States

Evaluating Pain Outcomes of Caudal vs Ilioinguinal Nerve Block in Children Undergoing Hernia Repair

First Posted Date
2017-02-03
Last Posted Date
2017-11-14
Lead Sponsor
Alberta Children's Hospital
Target Recruit Count
88
Registration Number
NCT03041948
Locations
🇨🇦

Alberta Children's Hospital, Calgary, Alberta, Canada

🇨🇦

Royal University Hospital/University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Oral Ketorolac for Pain Relief During IUD Insertion

Phase 4
Completed
Conditions
Interventions
First Posted Date
2017-01-26
Last Posted Date
2018-09-26
Lead Sponsor
OhioHealth
Target Recruit Count
71
Registration Number
NCT03031795

Efficacy of Pethidine, Ketorolac And Xylocaine Gel As Analgesics For Pain Control In Shockwave Lithotripsy

First Posted Date
2017-01-26
Last Posted Date
2018-05-29
Lead Sponsor
Mansoura University
Target Recruit Count
165
Registration Number
NCT03032458
Locations
🇪🇬

Urology and Nephrology Center, Mansourah, Aldakahlia, Egypt

TPI Medication Comparison - Ketorolac, Lidocaine, or Dexamethasone

First Posted Date
2017-01-23
Last Posted Date
2020-11-18
Lead Sponsor
University of Utah
Target Recruit Count
10
Registration Number
NCT03028012
Locations
🇺🇸

University of Utah Orthopaedic Center, Salt Lake City, Utah, United States

Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn

First Posted Date
2017-01-02
Last Posted Date
2017-08-16
Lead Sponsor
Nova Scotia Health Authority
Registration Number
NCT03007381

Evaluating Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision

First Posted Date
2016-11-28
Last Posted Date
2018-06-29
Lead Sponsor
Alberta Children's Hospital
Target Recruit Count
30
Registration Number
NCT02973958
Locations
🇨🇦

Alberta Children's Hospital, Calgary, Alberta, Canada

A Trial to Assess the Pain-control Efficacy of Intra-articular Toradol Compared to Oral NSAIDs

Phase 4
Withdrawn
Conditions
Interventions
First Posted Date
2016-11-17
Last Posted Date
2020-11-19
Lead Sponsor
The University of Texas Health Science Center, Houston
Registration Number
NCT02966288
© Copyright 2024. All Rights Reserved by MedPath